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ABSTRACT 
Type-2 Diabetes Mellitus is a persistent health problem that requires innovative 
strategies to improve health and needs a multifactorial approach for the treatment. 
Madhupramehari Vati an Ayurvedic medicine consists of maximum number of Rasayana 
and Yogvahi drug i.e. Shilajatu (Black Bitumen), Swarnamakshika (Copper Pyrites), 
Amalaki (Emblica officinalis), Haridra (Curcuma longa) etc. which act as a Naimittika 
Rasayana. The total number of Patients 33 were divided into two groups named as group 
A (16 patients of prediabetes or impaired fasting glucose {IFG} and impaired glucose 
tolerance {IGT} clinically diagnosed) was given Madhupramehari Vati 500 mg in tablet 
form twice a day before taking meal for 60 days and group B (17 patients of diabetics 
clinically diagnosed) was given Madhupramehari Vati 500 mg with Triphala Kwath of 50 
ml twice a day before taking meal for 60 days. The patients were provided a proper diet 
chart planned according to the classics and to maintain a routine of 30 minutes walk in 
the morning and in the evening hours, Pranayama daily for 30 min in morning hours. 
Glycosylated hemoglobin (serum HbA1c) was evaluated in eight patients which showed 
statistically highly significant results. There were also statistically significant results in the 
fasting blood sugar (FBS) and post prandial blood sugar (PPBS) parameters, both groups. 
KEYWORDS: Madhupramehari Vati, Apathyanimittaja Prameha, Diabetes Mellitus, Hb1Ac, 
Pranayama, Naimittika Rasayana. 
INTRODUCTION
The World Health Organization (WHO) 
report shows that 32 million people had diabetes 
in the year 2000[1]. Type-2 diabetes is the result of 
a progressive impairment of pancreatic β-cell 
function in the setting of worsening insulin 
resistance. Studies have demonstrated that during 
progression to diabetes, β-cells have declining 
function and lose the first phase of insulin 
secretion, resulting in less than adequate 
suppression of hepatic glucose production 
following meals. Type-2 diabetes mellitus is one of 
the most prevalent life style disorders in present 
era. The disease affects more than 50 million 
Indians (7.1% of the Nation's adults) and kills 
about 1 million Indians in a year. In Ayurveda, the 
science of life mentions, ‘Madhumeha’ is 
considered as disease of vitiated Vata and Kapha 
Dosha and Agnimandya is present in Madhumeha. 
Acharya Charaka has used term “bahudrava 
shleshma tatha avabadha meda” in the description 
of Prameha and Dushyas involved in it are mainly 
Meda, Mamsa, Kleda, Shukra, Shonita, Vasa, Majja 
etc. are all Kapha vargiya. The trial drugs 
Madhupramehari Vati and Triphala Kwath are 
having properties of Naimittika Rasayana and 
Yogvahi. 
Aims and Objectives 
 To assess the efficacy of the Madhupramehari 
Vati in the management of a series of patients 
of Madhumeha in relation with D.M.II. 
 To assess the efficacy of the Madhupramehari 
Vati in the management of a Series of patients 
of Madhumeha in relation with D.M.II with 
"Triphala Kwath" as an Anupana. 
 To compare the effectiveness of 
Madhupramehari Vati and Madhupramehari 
Vati with Triphala Kwath.  
Materials and Methods 
  Madhupramehari Vati[2] having following 
contents: Vanga Bhasma (Stannum), Sudha 
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Shilajatu (Black Bitumen), Loha Bhasma (Ferrum), 
Swarnamakshika Bhasma (Copper Pyrites) in one 
part each and Lodhra Ghana (Symplocos racemasa, 
root), Udumbara Saar (Ficus golmerata root bark), 
Jambu (Syzygium Cumini, fruit seed), Daruharidra 
(Berberis aristata, root), Haridra (Curcuma longa, 
rhizome) in forth part of each. Firstly make 
Udumbara Saar and Lodhra Ghana than 75 gms 
each of Vanga Bhasma, Sudha Shilajatu, Loha 
Bhasma & Swarnamakshika Bhasma mixed in 
"Lodhra Ghana". Finally, each 300gms of Jambu 
Seeds Churna, Haridra Churna, Daruharidra 
Churna and Udumbara Saar mixed in "Lodhra 
Ghana". After mixing of all ingredients, a 500 mg 
tablet was prepared by adding Triphala Kwath. 
Triphala Kwath: Haritaki (Terminalia Chebula), 
Vibitaki (Terminalia bellerica), Amalaki (Emblica 
officinalis) in equal quantity and make Kwath in 
the dose of 50 ml with Madhu. Each 8 gms of 
Haritaki, Vibitaki and Amalaki packed in one 
pouch of total 24 gms for 1 day. This is used in 
twice a day. All the procedure was done in the 
department of Rasa Shastra and Bhaisajya 
Kalpana (pharmacy) at NIA, Jaipur. 
Selection of Cases: The study was an open trial, 
randomized, clinical trial using pretest-posttest 
design and the study population was collected 
from the OPD and IPD of P.G. Department of 
Kayachikitsa at Arogyashala, National Institute of 
Ayurveda and SSBH, Jaipur (Raj.) The study was 
conducted on 30 clinically and pathologically 
diagnosed patients of Madhumeha [DM 2].  
Inclusion Criteria 
 The following inclusion criteria was followed 
for selecting the patients- 
 Type II DM- patients 
 Patients having hyperglycemia confirmed 
by Laboratory Investigation. 
 Patients with impaired fasting glucose 
{IFG} and impaired glucose tolerance 
{IGT} clinically diagnosed. 
 Age group between 30-70 yrs of either sex. 
 Exclusion Criteria 
Following patients excluded from clinical trial: 
 Patients having Type - DM I [IDDM] 
 Age below 30 and above 70 years. 
 Patient of type II DM who are on Insulin 
therapy. 
 DM associated with any type of 
Malignancy. 
 DM with complications.  
 Diabetes insipidus. 
 Patient having any serious illness. 
 Drug induced DM. 
 FBS [>250mg/dl] 
 PPBS [>300mg/dl] 
 DM with coronary artery diseases. 
Parameters of evaluation: Subjective 
parameters: 
1) Prabhoot Mutrata (Polyurea) 
a) Quantity of urine 
1.50 to 2.00 litters / 24 hrs. : 0 
>2.00 to 2.50 litters / 24 hrs. : 1 
>2.50 to 3.00 litters / 24 hrs. : 2 
>3.00 litters / 24 hrs. : 3 
b) Frequency of urine 
3 – 5 times per day, no or 
rarely at night  
: 0 
6 – 8 times per day, 1 – 2 times 
per night 
: 1 
9 – 11 times per day, 3 – 4 
times per night 
: 2 
> 11 times per day, > 4 times 
per night 
: 3 
2) Pipasa - Adhika (Polydipsia) 
Feeling of thirst 7 – 9 times/24 
hours, either/or Intake of water 5 
– 7 times/24 hours with quantity 
1.5 – 2.0 litter/24 hours 
: 0 
Feeling of thirst 9 - 11 times/24 
hours, either/or Intake of water 7 - 
9 times/24 hours with quantity 2.0 
- 2.50 liter/24 hours 
: 1 
Feeling of thirst 11 – 13 times/24 
hours, either/or Intake of Water 9 
– 11 times/24 hours with quantity 
2.50 -3.00 liter/24hours 
: 2 
Feeling of thirst >13 times/24 
hours, either/or Intake of water 
>11 times/24 hours with quantity 
>3.00 liter/24 hours 
: 3 
3) Avila Mutrata (Turbidity in urine) 
 
Sp. 
Gravity 
Urine 
Sugar 
Alb. Total 
score 
score 
1020-
1025 (0) 
Nil (0) Nil (0) 0 0 
1026-
1030 (1) 
+ (1) + (1) 1-3 1 
1031-
1035 (2) 
++(2) ++(2) 2-6 2 
1036-
1040 (3) 
+++(3) +++(3) 3-9 3 
1041-
1045 (4)  
++++(4) ++++(4) 4-12 4 
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4) Kshudha Adhika (Polyphagia) 
As usual / routine(1 – 2 meals) : 0 
Slightly increased (3-4 meals) : 1 
Moderately increased (4– 5 
meals) 
: 2 
Markedly increased (> 5 meals) : 3 
5) Kara-Pada Suptata (numbness in hand and 
feet) 
No suptata : 0 
Kara-Pada Suptata incontinuous : 1 
Kara-Pada Suptata continuous 
but bearable & not severe 
: 2 
Kara-Pada Suptata continuous 
and severe & unbearable 
: 3 
6) Kar Pada Daha (Burning sensation in hands 
& feet) 
Absent : 0 
Occasional : 1 
Continuoes : 2 
Continuous & Require some 
medication 
: 3 
Continuous & Require some 
medication but doesn’t get 
relief 
: 4 
7) Swedadhikya (Perspiration) 
Sweating after some strenuous 
or heavy work or in hot & 
humid weather 
: 0 
Profuse sweating after 
moderate work and movement 
: 1 
Sweating after little extra work 
than routine and movement 
: 2 
Profuse sweating after routine 
work 
: 3 
Sweating even at rest or in cold 
climate 
: 4 
8) Daurbalya (Weakness) 
Can do routine exercise/work : 0 
Can do moderate exercise with 
hesitancy 
: 1 
Can do mild exercise only, with 
difficulty 
: 2 
Cannot do mild exercise too : 3 
9) Shula (Joint Pain) 
No pain : 0 
Pain in joint, routine 
movements normal 
: 1 
Pain in joint, slight limitations 
of movements 
: 2 
Pain in joint, limitations of 
movements with much reduced 
activity 
: 3 
10) ShramaSwasa (Dyspnoea) {ATS scale} 
Not troubled by shortness of 
breath on level or uphill 
: 0 
Troubled by shortness of breath 
on level or uphill 
: 1 
Walks slower than persons of 
same age 
: 2 
Stops after walking 100 yards  : 3 
Breathlessness at rest   
11) Nidradhikya (Sleep) 
Normal & sound sleep for 6 – 8 
hrs. /24 hrs. with feeling of 
lightness and relaxation in the 
body & mind 
: 0 
Sleep> 8 -9 hrs. /24 hrs. with 
slight heaviness in the body 
: 1 
Sleep >9- 10 hrs. /24 hrs. with 
heaviness in the body associated 
with Jrimbha 
: 2 
Sleep >10 hrs. /24 hrs. with 
heaviness in the body associated 
With Jrimbha & Tandra 
: 3 
12) Purishabadhdhata (Constipation) 
Stool passes as per normal 
schedule 
: 0 
Passes stool with strain, 
sometimes takes purgative 
: 1 
Passes stool after more than 24 
hours, frequently takes purgative 
: 2 
Passes stool after gap of one day, 
normal purgatives does not work 
: 3 
13) Mathunavaraisaya (Libido) 
Normal : 0 
Decreased frequency with normal 
performance 
: 1 
Decrease frequency with 
insufficiency 
: 2 
No sexual stimulation at all : 3 
14) Pindikodveshtana (Cramps): 
No cramps : 0 
Cramps after walking more than 1 
km 
: 1 
Cramps after walking ½ km : 2 
Inability in walking even ½ km : 3 
15. Objective Parameters: Assessment of B.M.I. 
(weight in kg/height in meter2) 
18.5-24.9 : 0 
25 – 29.9 : 1 
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30 -34.9 : 2 
35 -39.9  3 
>40  : 4 
16) Laboratory Parameters 
 Hemoglobin, Total Leucocyte Count (TLC), 
differential leucocyte count, Erythrocyte 
Sedimentation Rate (ESR), CBC. 
 Urine for routine and microscopic 
examination. 
 Biochemical investigations: FBS, PPBS, 
lipid profile, and Serum Glycosylated 
Haemoglobin (S. HbA1c).   
Treatment protocol 
In group A (16) patients with clinically 
diagnosed impaired fasting glucose {IFG: 100 to 
125 mg/dl} and impaired glucose tolerance {IGT: 
140 to 199 mg/dl}, not taking any medication 
were administered Madhupramehari Vati 500 mg 
in tablet form twice a day before taking meal for 
60 days and group B (17) patients with diagnosed 
type-2 diabetes mellitus(FBS >126 mg/dl and 
PPBS >200 mg/dl), not taking any medication 
were given Madhupramehari Vati 500 mg with 
Triphala Kwath of 50 ml twice a day before taking 
meal for 60 days.  
The patients under both the groups were 
provided a proper diet chart planned according to 
the classics and keeping glycemic index of the 
dietary substances and calorie requirement of the 
patients. Simultaneously they were asked to 
maintain a routine of 30 min walk in the morning 
and in the evening hours, Pranayama a daily of 30 
min in morning hours, 7 days a week. There was 
Fortnight (15 day) of follow-up, after completion 
of 2 months of the treatment 
Statistical analysis 
Evaluation of the data through statistical 
estimation within the group and comparison 
between the groups BT (Before Treatment) and 
AT (After Treatment) were assessed using paired 
and unpaired Student's t test, respectively. For 
comparison of the subjective parameters, Mann 
Whitney test was used and for comparison of the 
objective parameters, unpair t test with Welch 
correction was used. P < 0.05 was considered as 
statistically significant, P>0.05 was considered as 
statistically non significant. 
Results and Observation 
 A total of 33 patients, in group A, 15 and in 
group B, 15 patients completed the study. In the 
clinical study maximum number (33%) of patients 
belonged to the age group of 40-49 years and 70% 
were males. Majority of them belonged to Hindu 
religion (70%), married (97%), urban area (70%), 
govt. employees (36%) and educated (84%), non 
vegetarian (55.5%) and were from middle class 
(52%) of the society. Positive family history for 
type-2 diabetes was found in 42% of the patients.  
Mean FBS and PPBS values were 121 
mg/dl and 171.46 mg/dl in group A, respectively. 
In group B, mean FBS and PPBS values were 
172.66 mg/dl and 235.7 mg/dl, respectively, 
before the commencement of the treatment. In 
group A, mean serum cholesterol and serum 
triglyceride values were 187.33 mg/dl and 148.53 
mg/dl, respectively. In group B, S. cholesterol and 
S. triglyceride were having mean values of 213.73 
mg/dl and 171.33 mg/dl, respectively. In group A, 
mean serum LDL and serum VLDL values were 
107.56 mg/dl and 29.45 mg/dl, respectively. In 
group B, S. LDL and S. VLDL were having mean 
values of 124.53 mg/dl and 35.21 mg/dl, 
respectively. In group A, mean value of S. HDL 
(Serum High Density Lipoprotein) was 49.13 
mg/dl and in group B mean value for S. HDL was 
51.33 mg/dl. Mean S. HbA1c value in eight 
patients of group B was 7.22 %. In group A, 2+ 
urine sugar was present in 13.33 % of the patients 
and 1+ in 18.75 % patients. In group B, 4+ urine 
sugar was found in 11.76 % of the patients, 
followed by 3+ in 17.64 %, 2+ in 23.52 %, and 1+ 
urine sugar in 29.4 % of the patients. 
Effect of the therapies on subjective 
parameters 
There was a statistically significant result 
on subjective parameters in both groups except in 
Hasta Padtal Daha, Swedadhikya, Shrama Swasa 
Mathunavaraisaya, and Pindikodveshtana in group 
A and Swedadhikya, Sandi Shula in Group B, 
respectively. [Table No.1 & 2] 
Effect of the therapies on Objective parameters 
In Fasting blood sugar values (FBS), there 
was statistically high significant (P < 0.001) 
reduction of 13.88 % in group A and 14.98 % in 
group B, respectively. In Post Prandial blood sugar 
(PPBS), there was statistically highly significant (P 
< 0.001) reduction of 11.93 % in group A and 
10.76 % in group B, respectively. In urine sugar 
fasting, there was statistically non significant (P > 
0.05) reduction of 40 % in group A and 
statistically highly significant reduction (P < 
0.001) of 58.33 % in group B. In S. cholesterol, 
there was statistically significant (P < 0.05) 
reduction of 6.93 % in group A and statistically 
highly significant reduction (P < 0.001) of 13.06 % 
in group B. In S. triglyceride, there was statistically 
non significant (P > 0.05) reduction of 12.74 % in 
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group A and statistically significant reduction (P < 
0.05) of 12.52 % in group B. In S. HDL, there was 
statistically significant increase (P < 0.05) of 4.34 
% in group A and statistically non significant 
increase (P > 0.05) of 3.89 % in group B. In S. LDL, 
there was statistically non significant (P > 0.05) 
reduction of 4.12 % in group A and statistically 
highly significant reduction (P < 0.001) of 14.73 % 
in group B. In S. VLDL, there was statistically non 
significant (P > 0.05) reduction of 4.25 % in group 
A and statistically significant reduction (P < 0.05) 
of 17.03 % in group B. [Table No. 3&4]. In BMI, 
there was statistically non significant (P > 0.05) 
reduction of 27.27 % in group A and statistically 
significant reduction (P < 0.05) of 27.27 % in 
group B. [Table No. 5&6]. There was insignificant 
increase in S. creatinine and S. urea in group A and 
group B. [Table No. 7]. There was statistically 
highly significant (P < 0.001) reduction of 7.78 % 
in S. HbA1c. [Table No. 8]. 
In intergroup comparison, subjective 
symptoms Kar-Pada Suptata, ShramaSwasa shows 
good relief in group B than group A and 
Laboratory parameters Fasting Blood Sugar, LDL 
shows good relief in group B than group A. [Table 
No. 9,10,11] 
DISCUSSION 
Ayurvedic texts mention Prameha as one 
of the first disease as a manifestation of obesity, 
which is the most prominent predisposing factor 
in the incident of type-2 diabetes mellitus. Life 
style and diet style factors such as sedentary 
habits, high sugar content food articles such as 
milk products, and sweets, which make an 
individual prone for the incidence of type-2 
diabetes mellitus, are also mentioned in Ayurvedic 
texts as predisposing factors for Apathyanimittaja 
Prameha. Thus in this study, the treatment regime 
both in the form of lifestyle modifications as well 
as pharmacological intervention used. 
Madhupramehari Vati provided significant relief in 
almost all the cardinal symptoms. In FBS, there 
was statistically high significant (P < 0.001) 
reduction of 13.88 % in group A and 14.98 % in 
group B, respectively. Reduction of fasting blood 
glucose can be attributed β-cell protective and 
regenerative effect of the drugs like Shilajatu[3], 
Daruharidra, Haridra, Udumbara[4] and Amalaki in 
the combination which might have improved the 
basal insulin secretion and thus, might have 
reduced the hepatic gluconeogenesis also. In PPBS 
and Urine sugar showed statistically significant. It 
can be attributed insulin secretagogues effects and 
increase the glucose uptake in insulin sensitive 
tissues such as muscles and fat, also such drugs 
like Haridra, Jambu[5] and Triphala. Triphala[6] 
proves an antibacterial, antiviral, antioxidant, 
maintain GIT motility, and have Lipid Lowering 
and Antiatherosclerotic Effects.  
The Rasa like Tikta has also potency to improve 
the basic cellular metabolism due to their 
Shodhana properties while Kasaya Rasa not only 
reduces the peripheral resistance as well as 
clinical manifestation of the disease. Katu rasa 
stimulates Pachakagni desiccants the food, 
removes obstruction and dilates the passages and 
allays Kapha Doshas. Its main pharmacological 
action is Amapachana and make Ama stable (it 
obstructs the processing of product of digestive 
impairment i.e. Ama) which helps in glucose 
uptake in insulin sensitive tissues like as muscle, 
fats etc. by enhancing activity of insulin receptor. 
(Aavaranagana effects). 
Madhura Rasa being habituated since birth 
produces greater strength in Srotasa, Dhatus 
(tissues) and improves the strength of Oja due to 
their Ojovardhaka, Rasayana and Yogvahi 
properties which play an important role in 
pathogenesis of Madhumeha. In pathogenesis of 
Madhumeha, Vata Dosha is predominant factor. 
For controlling of Vata Dosha, the contents of 
Madhupramehari vati and Triphala Kwath have 
properties of Rasayana and Yogvahi effects.  
There was statistically highly significant 
reduction (P < 0.001) in S. HbA1c levels carried 
out in a selected number (n =8) of the patients in 
group B. This reduction can be attributed to the 
multifactorial, i.e., Pramehaghna (Jambu, Amalaki, 
Haridra etc.), Medohara (Haridra, Udumbara etc.), 
Rasayana[7] (Triphala, Amalaka etc.) effect of the 
ingredients of the combination. Significant 
reduction in S.HbA1c levels shows good glycemic 
control for the long term as well as significant 
improvement in the lipid profile besides reduction 
in oxidative stress related to hyperglycemia. There 
was insignificant results in the S. urea and S. 
creatinine indicate that there is no harmful in the 
renal functions and thus Madhupramehari Vati 
does not cause any renal impairment.  
CONCLUSION 
The treatment regime mentioned for 
Madhumeha can be a worth for the management 
of the type-2 diabetes by countering its complex 
pathology. The Pramehaghna (Antidiabetic), 
Medohara (Antihyperlipidemic), and Rasayana 
(Anti-oxidant and rejuvenate action) property of 
the Ayurvedic drugs not only ensures good 
glycemic control when supported by Pathya and 
Apathya mentioned for Prameha but also will 
delay its complications. 
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Table 1: Table showing Effect of therapeutic trial on clinical symptomatology in 15 patients of 
Madhumeha (DM) on Group A 
Variable Mean Mean 
Diff. 
S.D. ± S.E. ± Paired 
t-test 
P-value % Relief Sign. 
BT AT 
Prabhoot Mutrata 
(polyurea) 
a)Quantity of urine 
2.13 1.2 0.93 0.25 
 
0.06 14 <0.001 43.75 H.S. 
b) Frequency of urine 1.46 0.6 0.86 0.35 0.09 9.53 <0.001 59.09 H.S. 
Pipasaadhikya 
 (Polydipsia) 
1.4 0.8  0.6 0.50 0.13 4.58 <0.05 42.85 S. 
Avila mutrata 
(Turbidity in urine) 
1.33 0.66  0.66 0.48 0.12 5.29 <0.05 50 S. 
Kshudhadikya 
(Polyphagia) 
1.4 
 
1.13 
 
0.26 
 
0.70 
 
0.18 
 
1.46 
 
>0.05 19.04 
 
N.S. 
Kar-Pada Suptata 
 (Numbness in hand 
and feet) 
0.73 0.33 0.4 0.50 0.13  3.05 <0.05 54.54 S. 
KarPada Daha 
(Burning in hand and 
feet 
0.73 0.4  0.33  0.48 0.12 2.64 >0.05 45.45 N.S. 
Swedadhikya 
 (Perspiration) 
1 0.66 0.33 0.81 0.21 1.58 >0.05 33.33 N.S. 
Table 2: Table showing Effect of therapeutic trial on clinical symptomatology in 15 patients of 
Madhumeha (DM) on Group B 
Variable 
 
Mean Mean 
Diff. 
S.D. 
± 
S.E. ± Paired 
t-test 
P-
value 
% Relief Sign. 
BT AT 
Prabhoot Mutrata 
(polyurea) 
a)Quantity of urine 
2 1.13 0.86 0.51 
 
0.13 6.5 <0.001 43.33 
 
H.S. 
b) Frequency of urine  1.6 0.93 0.66 0.48 0.12 5.29 <0.05 41.66 S. 
Pipasaadhikya 
 (Polydipsia) 
1.8 
 
0.93 
 
 0.86 
 
0.35 
 
 0.09 
 
9.53 
 
<0.001 48.14 
 
H.S. 
Avila mutrata 
(Turbidity in urine) 
2 1.13  0.86 0.35  0.09 9.53 <0.001 43.33 H.S. 
Kshudhadikya 
(Polyphagia) 
1.8 1.33 0.53 0.63 0.16 3.22 <0.05 28.57 S. 
Kar-Pada Suptata 
 (Numbness in hand 
and feet) 
1.6 0.66 0.93 0.25 0.06  14 <0.001 58.33 H.S. 
KarPada Daha 
(Burning in hand and 
1.06 0.6  0.46  0.51 0.13 3.5 <0.05 43.75 S. 
Daurbalya 
 (weakness) 
1.4 
 
 0.6 
 
0.8 
 
0.41 
 
0.10 
 
0.02 
 
<0.001 57.14 
 
H.S. 
 Sandhi Shula 
(Pain in joints) 
1.06  0.6 0.46 0.63 0.16  2.82 <0.05 43.75 S. 
Shramaswasa 
 (dyspnoea) 
1.13 0.93 0.2  0.67 0.17 1.14 >0.05 17.64 
 
N.S. 
Nidradhikya (Sleep) 1.13 0.33 0.8 0.41 0.10 7.48 <0.001 70.58 H.S. 
Purishabadhdhata 
(Constipation) 
1.53 0.53 1 0.65 0.16 5.91 <0.001 65.21 
 
H.S. 
Mathuna Varyasaya  
 (loss of libido) 
1.2 0.93  0.26 0.59 0.15 1.73  >0.05 22.22 N.S. 
Pindikodveshtana 
(Cramps) 
0.93 0.6  0.33  0.72 0.18  1.78  >0.05  35.71 N.S. 
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feets 
Swedadhikya 
(Perspiration) 
1.13 1 0.13 0.83 0.21 0.61 >0.05 11.76 N.S. 
Table 3: Table showing Effect of therapeutic trial on Laboratory parameters in 15 patients of 
Madhumeha (DM) based on Group A 
 Variable 
 
Mean Mean 
Diff. 
S.D. 
± 
S.E. 
± 
Paired t-
test 
P-
value 
% 
Relief 
Sign. 
BT AT 
Fasting Blood Sugar 
(mg/dl) 
121 104.2 16.8 7.58 1.95 8.57 <0.001 13.8 H.S. 
Post Prandial Blood 
Sugar (mg/dl) 
171.4 
 
151 
 
20.4 
 
11.38 
 
2.94 
 
6.96 
 
<0.001 11.93 
 
 H.S. 
Urine Sugar(fasting) 0.33 0.2 0.13 0.51 0.13 1 >0.05  40 N.S. 
S. Cholesterol mg/dl 187.3 174.3 13 17.3 4.47 2.9 <0.05 6.93 S. 
S. Triglycerides mg/dl 148.5 129.6 18.93 37.55 9.69 1.95 >0.05 12.74 N.S. 
HDL mg/dl 49.13 51.2 2.13 2.16 0.55 3.81 <0.05 4.34 S. 
LDL mg/dl 107.5 103.1 4.43 18.3 4.72 0.93 >0.05 4.12 N.S. 
VLDL mg/dl 29.45 28.2 1.25 8.96 2.31 0.54 >0.05 4.25 N.S. 
Table 4: Table showing Effect of therapeutic trial on Laboratory parameters in 15 patients of 
Madhumeha (DM) on Group B 
 Variable 
 
Mean Mean 
Diff. 
S.D. 
± 
S.E. ± Paired t-
test 
P-
value 
% 
Relief 
Sign. 
BT AT 
Fasting Blood Sugar 
(mg/dl) 
172.6 
 
146.8 
 
25.86 
 
15.66 
 
4.04 
 
 6.39 
 
<0.001 14.98 
 
H.S. 
Post Prandial Blood Sugar 
(mg/dl) 
235.7 
 
210. 
 
25.36 
 
21.95 
 
5.66 
 
4.47 
 
<0.001 10.76 
 
 H .S. 
Urine Sugar(fasting) 1.6 0.66 0.93 0.593 0.15 6.08 <0.001 58.33 H.S. 
S. Cholesterol mg/dl 213.7 185.8 27.93 23.0 5.93 4.70 <0.001 13.06 H.S. 
S. Triglycerides mg/dl 171.3 149.8 21.46 30.31 7.82 2.74 <0.05 12.52 S. 
HDL mg/dl 51.3 53.33 2 6.40 1.65 1.65 >0.05 3.89 N.S. 
LDL mg/dl 124.5 106.1 18.34 8.90 2.29 0.24 <0.001 14.73 H.S. 
VLDL mg/dl 35.2 29.21 6 6.34 1.63 0.24 <0.05 17.03 S. 
Table 5: Table showing Effect of therapeutic trial on objective parameters in 15 patients of 
Madhumeha (DM) on Group A 
Variable 
 
Mean Mean 
Diff. 
S.D. 
± 
S.E. 
± 
Paired t-
test 
P-
value 
% 
Relief 
Sign. 
BT AT 
1.Weight (Kg) 67.46 65.73 1.73 2.43 0.62 2.75 <0.05 2.56 S. 
2. BMI (Kg/m2) 0.73 0.53 0.2 0.41  0.10 1.87 >0.05 27.27  N.S. 
Table 6: Table showing Effect of therapeutic trial on objective parameters in 15 patients of 
Madhumeha (DM) on Group B 
Variable Mean Mean Diff. S.D. ± S.E. ± Paired t-test P-value % Relief Sign. 
BT AT 
1.Weight (Kg) 72 69.2 2.8 4.95 1.28 2.18 <0.05 3.88 S. 
Daurbalya (weakness) 1.46 0.66 0.8 0.56  0.14 5.52 <0.001 54.54 H.S. 
 Sandhi Shula (Pain in 
joints) 
1.2 1.06 0.13 0.74 0.19  0.69 >0.05 11.11 N.S. 
Shramaswasa 
 (dyspnoea) 
2.13 1.46 0.66  0.61 0.15 4.18 <0.05 31.25 S. 
Nidradhikya (Sleep) 1.53 0.46 1.06 0.25 0.06 16 <0.001 69.56 H.S. 
Purishabadhdhata 
(Constipation) 
1.8 0.8  1 0.53 0.13 7.24 <0.001 55.55 H.S. 
Mathuna Varyasaya  
 (Libido) 
1.4 1.06 0.33 0.72 0.18 1.78 >0.05 23.80 N.S. 
Pindikodveshtana 
(Cramps) 
1.13 0.73  0.4  0.63 0.16  2.44 >0.05 35.29 
 
N.S. 
Naresh Kumar Kumawat et al. Madhupramehari Vati in the Management of Apathyanimittaja Prameha 
 Available online at : http://ijapr.in Page 58 
2. BMI (Kg/m2) 1.2 0.86 0.33 0.48 0.12 2.64 <0.05 27.77 S. 
Table 7: Table showing Effect of therapeutic trial on S. Creatinine and S. Uric acid in 8 patients of 
Madhumeha (Diabetes Mellitus) (n=8) 
Variable Mean Mean 
Diff. 
S.D. 
± 
S.E. ± Paired t-
test 
P-
value 
% 
Relief 
Sign. 
BT AT 
1.S.Creatinine mg/dl 5.56 5.7 0.13 0.26 0.092 0.122  >0.05 2.47 N.S. 
2. S. Uric acid mg/dl 1.03 1.11 0.07 0.23 0.081 0.122 >0.05 7.22 N.S. 
Table 8: Table showing Effect of therapeutic trial on Glycosylated Hemoglobin (Hb1Ac) in 8 
patients of Madhumeha (Diabetes Mellitus) (n=8)
Variable Mean Mean 
Diff. 
S.D. 
± 
S.E. ± Paired t-
test 
P-value % Relief Sign. 
BT AT 
Hb1Ac 7.22 6.66 0.56 0.25 0.08 6.35 <0.001 7.78 H.S. 
Table 9: Intergroup comparison in subjective symptoms (Group A and Group B) 
Variable Mann Whitney U value P-value Sign. 
1.Prabhoot Mutrata (polyurea) 
a)Quantity of urine 
104.50 0.63 N.S. 
b) Frequency of urine 90 0.21 N.S. 
2.Pipasaadhikya (Polydipsia) 82.5 0.11 N.S. 
3.Avila mutrata (Turbidity in urine) 90 0.21 N.S. 
4. Kshudhadikya (Polyphagia) 88.5 0.21 N.S. 
5.Kar-Pada Suptata (Numbness in hand and feet) 52.5 0.002 S. 
6.KarPada Daha (Burning in hand and feets 97.5 0.47 N.S. 
7.Swedadhikya (Perspiration) 97 0.50 N.S. 
8.Daurbalya (weakness) 111 0.95  N.S. 
 9. Sandhi Shula (Pain in joints) 84.5 0.21 N.S. 
10.ShramaSwasa (dyspnoea) 68.5 0.04 S. 
11.Nidradhikya (Sleep) 84 0.04 S. 
12.Purishabadhdhata (Constipation) 107 0.77 N.S. 
13.Mathuna Varyasaya (Libido) 103.50 0.69 N.S. 
14.Pindikodveshtana (Cramps) 108.50 0.87 N.S. 
Table 10: Intergroup comparison in objective symptoms (Group A and Group B) 
Variable t value P value Sign. 
1.Weight (Kg) 0.74 0.46 N.S. 
2. BMI (Kg/m2) 0.80 0.42 N.S. 
Table 11: Intergroup comparison in Laboratory parameters (Group A and Group B)
Hb gm% 1.825 0.082 N.S. 
 TLC / cumm 0.1448 0.88 N.S. 
TRBC /mill/𝝁L 0.4693 0.64 N.S. 
TPLC/ lac/𝝁L 0.00 0.9 N.S. 
ESR(mm/h) 0.8541 0.40 N.S. 
Fasting Blood Sugar (mg/dl) 2.017 0.05 N.S. 
PP Blood Sugar (mg/dl) 0.7672 0.45 N.S. 
Urine Sugar(fasting) 3.938 0.0005 H.S. 
S. Cholesterol mg/dl 2.008 0.055 N.S. 
S. Triglycerides mg/dl 0.2033 0.840 N.S. 
HDL mg/dl 0.076 0.940 N.S. 
LDL mg/dl 2.647 0.015 S. 
VLDL mg/dl 1.674 0.106 N.S. 
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